Christer Halldin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Christer Halldin has a total of 29 co-authors. Here are the top co-authors by number of shared publications:
Balázs Gulyás
Karolinska Hospital
3 shared publicationsJudit Sóvágó
Karolinska Hospital
3 shared publicationsJukka Hiltunen
Helsinki University, Department of Chemistry, Laboratory of Radiochemistry, Helsinki, Finland
3 shared publicationsLars Farde
Karolinska Hospital
3 shared publicationsJari Tarkiainen
Karolinska Institutet, Department of Clinical Neuroscience, Section of Psychiatry, Stockholm, Sweden
2 shared publications- Johan Sandell
Karolinska Institutet, Department of Clinical Neuroscience, Psychiatry Section, Karolinska Hospital, S-171 76 Stockholm, Sweden
2 shared publications
Latest Publications
- 2 December 2005
- Published by Springer Nature in Molecular Imaging and Biology
- Vol. 8 (1) , 1-8
Synthesis and Positron Emission Tomography Evaluation of Three Norepinephrine Transporter Radioligands: [C-11]Desipramine, [C-11]Talopram and [C-11]Talsupram
Desipramine (DMI), talopram and talsupram, three of the most potent norepinephrine transporter (NET) inhibitors reported to date, were radiolabeled in high yields and at high specific radioactivity (58–75 GBq/μmol) by the methylation of nor-precursors with [C-11]methyl triflate. The regional brain distribution of each radioligand following intravenous injection into cynomolgus monkey was examined in vivo with positron emission tomography (PET). For all three radioligands, the regional brain distribution of radioactivity was slightly heterogeneous, with higher uptake of radioactivity in the mesencephalon, thalamus and lower brainstem than in striatum. The rank order of maximal brain radioactivity (as percentage of injected dose) was [11C]DMI (2.7%) > [11C]talsupram (1.3%) > [11C]talopram (0.7%). The appearance of radioactive metabolites in plasma was similar for each radioligand (75–85% of radioactivity in plasma at 45 min). These metabolites were all more polar than their parent radioligand. The data show that these radioligands are inferior to existing radioligands for the study of brain NET with PET in vivo.
- 2 December 2005
- Published by Springer Nature in Molecular Imaging and Biology
- Vol. 8 (1) , 1-8
Synthesis and Positron Emission Tomography Evaluation of Three Norepinephrine Transporter Radioligands: [C-11]Desipramine, [C-11]Talopram and [C-11]Talsupram
Desipramine (DMI), talopram and talsupram, three of the most potent norepinephrine transporter (NET) inhibitors reported to date, were radiolabeled in high yields and at high specific radioactivity (58–75 GBq/μmol) by the methylation of nor-precursors with [C-11]methyl triflate. The regional brain distribution of each radioligand following intravenous injection into cynomolgus monkey was examined in vivo with positron emission tomography (PET). For all three radioligands, the regional brain distribution of radioactivity was slightly heterogeneous, with higher uptake of radioactivity in the mesencephalon, thalamus and lower brainstem than in striatum. The rank order of maximal brain radioactivity (as percentage of injected dose) was [11C]DMI (2.7%) > [11C]talsupram (1.3%) > [11C]talopram (0.7%). The appearance of radioactive metabolites in plasma was similar for each radioligand (75–85% of radioactivity in plasma at 45 min). These metabolites were all more polar than their parent radioligand. The data show that these radioligands are inferior to existing radioligands for the study of brain NET with PET in vivo.
[11C]MADAM, a new serotonin transporter radioligand characterized in the monkey brain by PET
The aim of this study was to explore the potential of a new selective serotonin transporter (5-HTT) inhibitor, N,N-dimethyl-2-(2-amino-4-methylphenylthio)benzylamine (MADAM, Ki = 1.65 nM), as a PET radioligand for examination of 5-HTT in the nonhuman primate brain. MADAM was radiolabeled by an N-methylation reaction using [11C]methyl triflate and the binding was characterized by PET in four cynomolgus monkeys. Metabolite levels in plasma were measured by gradient high-performance liquid chromatography (HPLC). The radiochemical incorporation yield of [11C]MADAM was 75–80% and the specific radioactivity at the time of administration was 34–652 GBq/μmol (n = 8). The highest uptake of radioactivity was observed in striatum, thalamus, mesencephalon, and the lower brainstem. Lower binding was detected in neocortex and the lowest radioactive uptake was found in the cerebellum. This distribution is in accordance with the known expression of 5-HTT in vitro. The fraction of the total radioactivity in monkey plasma representing unchanged [11C]MADAM was 20% at 45 min after injection, as measured by gradient HPLC. Pretreatment measurements, using unlabeled citalopram, GBR 12909, and maprotiline, as well as a displacement measurement, using unlabeled MADAM, confirmed that [11C]MADAM binds selectively and reversibly to 5-HTT, and support the use of the cerebellum as reference region. The present characterization of binding in the monkey brain suggests that [11C]MADAM is a potential PET radioligand for quantitative studies of 5-HTT binding in the human brain. Synapse 58:173–183, 2005.
[11C]MADAM, a new serotonin transporter radioligand characterized in the monkey brain by PET
The aim of this study was to explore the potential of a new selective serotonin transporter (5-HTT) inhibitor, N,N-dimethyl-2-(2-amino-4-methylphenylthio)benzylamine (MADAM, Ki = 1.65 nM), as a PET radioligand for examination of 5-HTT in the nonhuman primate brain. MADAM was radiolabeled by an N-methylation reaction using [11C]methyl triflate and the binding was characterized by PET in four cynomolgus monkeys. Metabolite levels in plasma were measured by gradient high-performance liquid chromatography (HPLC). The radiochemical incorporation yield of [11C]MADAM was 75–80% and the specific radioactivity at the time of administration was 34–652 GBq/μmol (n = 8). The highest uptake of radioactivity was observed in striatum, thalamus, mesencephalon, and the lower brainstem. Lower binding was detected in neocortex and the lowest radioactive uptake was found in the cerebellum. This distribution is in accordance with the known expression of 5-HTT in vitro. The fraction of the total radioactivity in monkey plasma representing unchanged [11C]MADAM was 20% at 45 min after injection, as measured by gradient HPLC. Pretreatment measurements, using unlabeled citalopram, GBR 12909, and maprotiline, as well as a displacement measurement, using unlabeled MADAM, confirmed that [11C]MADAM binds selectively and reversibly to 5-HTT, and support the use of the cerebellum as reference region. The present characterization of binding in the monkey brain suggests that [11C]MADAM is a potential PET radioligand for quantitative studies of 5-HTT binding in the human brain. Synapse 58:173–183, 2005.
- 5 May 2005
- Published by Elsevier in Nuclear Medicine and Biology
- Vol. 32 (4) , 353-360
A preliminary PET evaluation of the new dopamine D2 receptor agonist [11C]MNPA in cynomolgus monkey
- 5 May 2005
- Published by Elsevier in Nuclear Medicine and Biology
- Vol. 32 (4) , 353-360
A preliminary PET evaluation of the new dopamine D2 receptor agonist [11C]MNPA in cynomolgus monkey
- 2 November 2001
- Published by Wiley in Journal of Labelled Compounds and Radiopharmaceuticals
- Vol. 44 (14) , 1013-1023
Carbon-11 labelling of MADAM in two different positions: a highly selective PET radioligand for the serotonin transporter
- 2 November 2001
- Published by Wiley in Journal of Labelled Compounds and Radiopharmaceuticals
- Vol. 44 (14) , 1013-1023
Carbon-11 labelling of MADAM in two different positions: a highly selective PET radioligand for the serotonin transporter
- 1 June 1998
- Published by Wiley in Journal of Labelled Compounds and Radiopharmaceuticals
- Vol. 41 (6) , 545-556
Improved syntheses of the PET radioligands, [11C]FLB 457, [11C]MDL 100907 and [11C]β-CIT-FE, by the use of [11C]methyl triflate
- 1 June 1998
- Published by Wiley in Journal of Labelled Compounds and Radiopharmaceuticals
- Vol. 41 (6) , 545-556
Improved syntheses of the PET radioligands, [11C]FLB 457, [11C]MDL 100907 and [11C]β-CIT-FE, by the use of [11C]methyl triflate
- 1 April 1998
- Published by Wiley in Human Psychopharmacology: Clinical and Experimental
- Vol. 13 (3) , 177-182
The metabolism of iodine-123 labelled 3-(5-cyclopropyl-1,2,4-oxadiazo-3-yl)-7-iodo-5,6-dihydro-5-methyl-6-oxo-4H-imidazo[1,5-a][1,4]benzodiazepine (NNC 13-8241) measured in human plasma is only minor
- 1 April 1998
- Published by Wiley in Human Psychopharmacology: Clinical and Experimental
- Vol. 13 (3) , 177-182
The metabolism of iodine-123 labelled 3-(5-cyclopropyl-1,2,4-oxadiazo-3-yl)-7-iodo-5,6-dihydro-5-methyl-6-oxo-4H-imidazo[1,5-a][1,4]benzodiazepine (NNC 13-8241) measured in human plasma is only minor